| 0.22 0 (0%) | 03-13 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Biora Therapeutics, Inc. is a biotechnology company focused on developing cutting-edge oral biotherapeutic solutions. The company's core efforts involve two main therapeutic programs: Targeted Therapeutics: This program utilizes an advanced ingestible smart capsule designed to deliver medications precisely within the gastrointestinal (GI) tract. The aim is to significantly improve therapies for inflammatory bowel diseases. Systemic Therapeutics: Through a specialized ingestible capsule, this initiative provides a needle-free method for administering biotherapeutics directly into the intestinal lining, thereby promoting more effective systemic absorption throughout the body. Furthermore, Biora is actively developing diagnostic devices. These tools are engineered to better characterize the digestive system and identify various GI conditions, such as small intestine bacterial overgrowth, by offering on-site diagnosis. Originally established in 2010 as Progenity, Inc., the company rebranded to Biora Therapeutics, Inc. in April 2022. This name change was made to reflect its concentrated strategic shift towards its therapeutics pipeline. Biora Therapeutics, Inc. is headquartered in San Diego, California.
Sun, 30 Aug 2026
Biora Therapeutics Inc (BIOR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Thu, 24 Apr 2025
Biora Therapeutics (BIOR) Stock Price, News & Analysis - Stock Titan
Mon, 31 Mar 2025
Biora's Fresh Start: Restructuring Success Fuels BioJet Platform Development - Stock Titan
Tue, 10 Dec 2024
Biora Therapeutics to be delisted from Nasdaq - Investing.com
Thu, 14 Nov 2024
Biora Therapeutics Inc (BIOR) Quarterly 10-Q Report - qz.com
Thu, 15 Aug 2024
BIOR: Second Quarter Results - scr.zacks.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|